跳到正文
心血管健康證據回顧4 分鐘閱讀

降壓治療對多數年齡段都降低心血管事件,85歲以上證據不明確

MoveVitals 編輯部 · 研究發表 · 解讀更新

原文:Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. · Lancet (London, England) · 2021 · 論文原文 ↗

先看重點

彙總51項試驗、358707名參與者的資料,收縮壓每降低5 mm Hg,55至84歲族群的主要心血管事件風險比約為0.91,而85歲及以上族群未見明確獲益(風險比0.99,95%置信區間0.87-1.12)。85歲及以上僅4788人,因此最高齡組的結論最不確定。

證據類型

證據回顧

解讀依據

公開摘要

閱讀重點

方法與適用範圍

研究在問什麼

過去指南常以年齡和血壓界值決定誰需要降壓藥,但對70歲以上族群和血壓升高不明顯的人,證據並不充分。作者檢驗了降壓對主要心血管事件的作用是否隨年齡和基線血壓而不同。

研究對象與方法

個體參與者資料統合分析,納入來自血壓降低治療試驗者協作組的隨機對照試驗,比較降壓藥與安慰劑、其他類別降壓藥,或強化與非強化降壓策略,每組追蹤至少1000人年,排除既往心力衰竭者。參與者按年齡(<55歲、55-64歲、65-74歲、75-84歲、85歲及以上)和基線收縮壓、舒張壓(以10 mm Hg為一檔)分組。採用按試驗分層的固定效應一步法Cox模型。主要結局為致死或非致死性中風、心肌梗死或缺血性心臟病、導致死亡或住院的心力衰竭的複合終點。

主要發現

以下為作者報告的結果。數值須連同族群和不確定性一起閱讀。

  1. 1
    共納入51項試驗的358707名參與者,年齡中位數65歲(四分位距59-75,範圍21至105歲):<55歲42960人(12.0%),55-64歲128437人(35.8%),65-74歲128506人(35.8%),75-84歲54016人(15.1%),85歲及以上4788人(1.3%)。
  2. 2
    收縮壓每降低5 mm Hg,主要心血管事件的風險比在<55歲為0.82(95%置信區間0.76-0.88),55-64歲為0.91(0.88-0.95),65-74歲為0.91(0.88-0.95),75-84歲為0.91(0.87-0.96),85歲及以上為0.99(0.87-1.12)(校正後互動作用P=0.050)。舒張壓降低3 mm Hg呈相似模式。
  3. 3
    絕對風險降低在高齡組更大(校正後互動作用P=0.024)。
  4. 4
    作者未發現各年齡組中相對獲益隨基線血壓不同而有臨床意義的差異,血壓低至120/70 mm Hg以下時亦然。

限制與不確定性

  1. 1
    85歲及以上人數少,該組區間(0.87-1.12)既可能有獲益也可能無獲益。
  2. 2
    年齡與療效的互動作用只是臨界水平(P=0.050),對年齡組之間的差異應謹慎解讀。
  3. 3
    納入的是每組至少1000人年的試驗,並排除既往心力衰竭者,結果未必適用於臨床中所有族群。
  4. 4
    本解讀僅基於摘要。

日常健康啟示

彙總的試驗提示,降壓藥在很寬的年齡和基線血壓範圍內都降低了心血管事件,單憑年齡不應排除治療。85歲以後的證據最弱。是否治療、如何治療應與醫師結合個人情況決定。

如何連結自己的資料

在家用血壓計、每次在相同條件下測量,有助於你和醫師了解血壓是否在朝目標變化。不要僅憑血壓計數值自行調整藥物,複診時帶上記錄即可。

如何理解這類證據

先看納入了哪些設計、文獻搜尋與偏誤評估如何完成,以及搜尋截止日期;發表新不代表底層證據都是最新的。

作者的結構化摘要 English

以下英文摘要依所記錄的開放授權轉載,屬於作者原始材料,並非 MoveVitals 解讀。上方已提供研究解讀,分別說明作者結果與本站解釋;重要結論可直接查核原文。

Background

The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline.

Methods

We did a meta-analysis using individual participant-level data from randomised controlled trials of pharmacological blood-pressure-lowering versus placebo or other classes of blood-pressure-lowering medications, or between more versus less intensive treatment strategies, which had at least 1000 persons-years of follow-up in each treatment group. Participants with previous history of heart failure were excluded. Data were obtained from the Blood Pressure Lowering Treatment Triallists' Collaboration. We pooled the data and categorised participants into baseline age groups (<55 years, 55-64 years, 65-74 years, 75-84 years, and ≥85 years) and blood pressure categories (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg systolic blood pressure and from <70 mm Hg to ≥110 mm Hg diastolic). We used a fixed effects one-stage approach and applied Cox proportional hazard models, stratified by trial, to analyse the data. The primary outcome was defined as either a composite of fatal or non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring hospital admission.

Findings

We included data from 358 707 participants from 51 randomised clinical trials. The age of participants at randomisation ranged from 21 years to 105 years (median 65 years [IQR 59-75]), with 42 960 (12·0%) participants younger than 55 years, 128 437 (35·8%) aged 55-64 years, 128 506 (35·8%) 65-74 years, 54 016 (15·1%) 75-84 years, and 4788 (1·3%) 85 years and older. The hazard ratios for the risk of major cardiovascular events per 5 mm Hg reduction in systolic blood pressure for each age group were 0·82 (95% CI 0·76-0·88) in individuals younger than 55 years, 0·91 (0·88-0·95) in those aged 55-64 years, 0·91 (0·88-0·95) in those aged 65-74 years, 0·91 (0·87-0·96) in those aged 75-84 years, and 0·99 (0·87-1·12) in those aged 85 years and older (adjusted p_(interaction)=0·050). Similar patterns of proportional risk reductions were observed for a 3 mm Hg reduction in diastolic blood pressure. Absolute risk reductions for major cardiovascular events varied by age and were larger in older groups (adjusted p_(interaction)=0·024). We did not find evidence for any clinically meaningful heterogeneity of relative treatment effects across different baseline blood pressure categories in any age group.

Interpretation

Pharmacological blood pressure reduction is effective into old age, with no evidence that relative risk reductions for prevention of major cardiovascular events vary by systolic or diastolic blood pressure levels at randomisation, down to less than 120/70 mm Hg. Pharmacological blood pressure reduction should, therefore, be considered an important treatment option regardless of age, with the removal of age-related blood-pressure thresholds from international guidelines.

Funding

British Heart Foundation, National Institute of Health Research Oxford Biomedical Research Centre, Oxford Martin School.

來源與署名

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.

Blood Pressure Lowering Treatment Trialists' Collaboration.

Lancet (London, England) · 2021-08-27

DOI: 10.1016/s0140-6736(21)01921-8 ↗PubMed · 34461040 ↗Europe PMC · 所記錄的開放授權: cc by ↗

摘要著作權歸原作者,依來源紀錄的開放授權轉載。中文譯文協助閱讀,英文摘要供查核術語及具體數值;本站的方法學解釋與作者結論分別呈現。

MoveVitals 編輯解讀 · 健康教育內容 · 未記錄個人臨床審閱

來源查核日期 2026-11-01

實用健康指南

放在一起讀

·觀察研究統合分析

晝夜活動節律紊亂與更高的死亡風險相關(109,365人)

在7項觀察性研究、共109,365名參與者中,晝夜活動對比較弱(相對振幅較低)與更高的心血管死亡風險(風險比[HR]1.50,95%置信區間1.13至1.98)和全因死亡風險(HR 1.46,95%置信區間1.27至1.68)相關。證據基礎小,又是觀察性的,不能說明改善節律就能降低風險,疾病本身也可能擾亂節律。

Journal of the American Heart Association

重點論文精講閱讀論文 →
·隨機試驗統合分析

五類運動都降低了靜息血壓,等長訓練降幅最大

彙總270項隨機試驗、共15,827名參與者的結果,有氧、抗阻、聯合、間歇和等長訓練與無介入對照組相比都降低了靜息血壓(各P<0.001),其中等長訓練降幅最大:收縮壓下降8.24 mm Hg,舒張壓下降4.00 mm Hg。各方式之間的排序部分來自間接比較,各試驗也不盡相同,所以排序不是個人的運動處方。

British Journal of Sports Medicine

重點論文精講閱讀論文 →
·隨機對照試驗

鹽替代品使中國農村高危族群的中風、主要心血管事件和死亡率下降

在中國農村600個村莊、20,995名有中風史或年齡在60歲及以上且有高血壓的人中,使用鹽替代品(氯化鈉75%、氯化鉀25%)的中風發生率低於普通鹽:平均追蹤4.74年,每1000人年29.14次對33.65次(率比0.86,95%置信區間0.77至0.96;P=0.006)。死亡也更低(率比0.88),嚴重高鉀血癥事件沒有顯著增多,但試驗為開放標籤設計,且在中國農村開展。

The New England Journal of Medicine

重點論文精講閱讀論文 →
·測量驗證研究/回顧

智慧手錶脈搏不規則提醒較少見,做貼片檢查者34%確有房顫

在419,297名沒有已知心房顫動(房顫)的蘋果手錶使用者中,0.52%收到脈搏不規則提醒;返還可用心電貼片的450人中,34%確認有房顫(97.5%置信區間29至39)。提醒發出時恰有貼片記錄的,通知的陽性預測值為0.84(95%置信區間0.76至0.92),但收到提醒者中僅20.8%返還了貼片,沒有收到提醒的人未被監測,所以手錶沒有提醒並不能排除房顫。

The New England Journal of Medicine

重點論文精講閱讀論文 →
心血管健康 →